The authors concluded that rescue percutaneous coronary intervention is associated with improved clinical outcomes for ST-segment myocardial infarction patients after failed fibrinolytic therapy, but there are potential risks. No significant clinical improvements were shown for fibrinolytic therapy and it may be associated with increased harm. Overall, the conclusions appear reliable.
Authors' objectives
To evaluate the effectiveness and safety of rescue percutaneous coronary intervention (PCI) and repeat fibrinolytic therapy, compared with conservative management, in patients with failed fibrinolytic therapy for ST-segment myocardial infarction (STEMI).
Searching
MEDLINE, EMBASE and the Cochrane Library were searched to February 2006 without language restrictions; the search terms were reported. Bibliographies of articles and reviews were also searched.
Study selection

Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion.
Specific interventions included in the review
Studies that compared rescue PCI or repeat fibrinolytic therapy with conservative therapy were eligible for inclusion. Conservative therapy was defined as no further immediate reperfusion therapy. In the included studies, the average time from administration of initial fibrinolytic therapy to rescue PCI ranged from 77 to 274 minutes. The average time from onset of initial symptoms to repeat fibrinolytic therapy ranged from 332 to 360 minutes where specified; the agent used was tissue plasminogen activator.
Participants included in the review
Studies enrolling STEMI patients who failed initial fibrinolytic therapy were eligible. Studies not restricted to STEMI patients were excluded. The reviewers accepted angiographic and clinical definitions for failed fibrinolytic therapy. The mean age of the patients in the included studies ranged from 56 to 63 years. Anterior wall infarction was present in between 41% and 100% of patients.
Outcomes assessed in the review
Clinical outcomes of interest included all-cause mortality, heart failure and reinfarction, while safety outcomes included stroke, major and minor bleeding; the original study definitions were used. The duration of follow-up ranged from the time of hospital discharge to 6 months.
How were decisions on the relevance of primary studies made?
Two reviewers independently assessed the eligibility of studies for inclusion. Any disagreements were resolved by consensus.
Assessment of study quality
Study quality was assessed using the 5-point Jadad scale, which evaluates the reporting of randomisation, blinding and withdrawals. The authors did not state how the validity assessment was performed.
